Back to homepage

Tag "quality of life"

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study

Authors: Giuseppe Cicero MD PhD, Raffaele Addeo MD, Rossella De Luca PhD, Giuseppe Lo Re MD PhD, Leonardo Gulotta MD, Pierenrico Marchesa MD, Gaspare Gulotta MD PhD

This study evaluates the safety and
efficacy of TAS-102 in heavily pretreated elderly patients with
metastatic colorectal cancer.

More

Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study

Authors: Hae-Jin Suh Oh MD, Ángeles Flórez Menéndez PhD, Víctor Sacristán Santos MD, Francisca Fernández Ribeiro PharmD, Lucía Vilanova-Trillo DNP, Manuel Constenla Figueiras PhD, Manuel Pereiro Ferreiros PhD

This study evaluates the impact of cutaneous adverse events on quality of life in outpatients receiving anticancer drugs and aims to determine the differences in quality of life between conventional chemotherapy versus targeted therapies.

More

Topical treatment of radiation-induced dermatitis: current issues and potential solutions

Authors: Nicola Alessandro Iacovelli MD, Yvan Torrente MD, PhD, Adriana Ciuffreda MD, Vittorio A Guardamagna MD, PhD, Marta Gentili MS, Luca Giacomelli PhD, Paola Sacerdote PhD

The aim of this paper is to discuss current knowledge on radiation-induced dermatitis and propose targets for the prevention/treatment of this
condition. On these bases, the characteristics of the ‘ideal’
compound to address this side effect will be described.

More

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK

Authors: Helene Cawston, Francois Bourhis, Jennifer Eriksson, Pierfrancesco Ruffo, Paolo D’Agostino, Marco Turini, Lee Schwartzberg, Alistair McGuire

Despite study limitations (study setting, time horizon, utility measure), the results suggest NEPA is cost effective for preventing CINV associated with HEC and MEC in the UK.

More